SRSF3 and CD276 have significant co-expression (P <0.05), and CD276 (B7-H3), as a possible immune checkpoint molecule, is predicted by researchers to become one of the most promising tumor immunotherapy targets (22). Here, SRSF3 is linked to neoplasm.